drugset
drugset / Trial / NCT03601507

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

NCT03601507 ↗

Phase 2 Terminated 9 enrolled University of Arizona National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2019-03-11
Primary completion
2022-05-24
Completion
2022-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpelisib Small molecule — Oral

Indications

oropharynx squamous cell carcinoma